- Home
- CABR vs QNRX Comparison
CABR vs QNRX Comparison
Compare CABR & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CABR | QNRX |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 10.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CABR | QNRX |
|---|---|---|
| Price | $0.97 | $8.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 218.5K | 32.1K |
| Earning Date | 03-20-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,493.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.06 | $5.01 |
| 52 Week High | $6.00 | $41.80 |
Technical Indicators
Market Signals| Indicator | CABR | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 40.07 |
| Support Level | $0.86 | $7.00 |
| Resistance Level | $1.09 | $8.01 |
| Average True Range (ATR) | 0.14 | 0.87 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 33.43 | 34.14 |
Price Performance
Historical ComparisonAbout CABR Caring Brands Inc.
Caring Brands Inc is a consumer wellness company that supports health and wellness through research and development. Its product pipeline addresses a range of conditions, including hair loss, eczema, burns, and sexual wellness. The majority of revenue is generated from the sale of OTC and consumer products, as well as licensing royalties.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.